Fixed-duration therapy with venetoclax plus obinutuzumab led to 60% reduction in the risk of progression or death compared with chlorambucil plus obinutuzumab, with benefit seen regardless of TP53 or IGHV mutation status, in previously untreated patients with chronic lymphocytic leukemia.
Patients with chronic lymphocytic leukemia (CLL) experience long-term progression-free survival benefits with 1 year of venetoclax plus obinutuzumab versus a chemotherapy-based regimen.
Data from two studies continue to show the long-term efficacy and safety of fixed-duration venetoclax combination regimens across different lines of therapy in.
Long-term data show that venetoclax combinations benefit progression free survival and overall survival in patients with or without previous treatment for chronic lymphocytic leukemia.
The highly-anticipated National Haematology Summit 2022 returned to an in-person event for its eighth year after two virtual iterations, writes Danielle